Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner

Oncotarget

Volumn 6, Issue 18, 2015, Pages 16396-16410

  Avtanski, Dimiter B ^a   Nagalingam, Arumugam ^a   Kuppusamy, Panjamurthy ^b   Bonner, Michael Y ^c   Arbiser, Jack L ^c,d   Saxena, Neeraj K ^b   Sharma, Dipali ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Honokiol; Leptin; miR 34a

Indexed keywords

BETA CATENIN; CYCLIN D1; GLYCOGEN SYNTHASE KINASE 3BETA; HONOKIOL; METASTASIS ASSOCIATED ANTIGEN 1; MICRORNA 34A; PROTEIN KINASE B; STAT3 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; WNT1 PROTEIN; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; CCND1 PROTEIN, HUMAN; HERBACEOUS AGENT; HISTONE DEACETYLASE; LEPTIN; LIGNAN; MICRORNA; MIRN34 MICRORNA, HUMAN; MTA1 PROTEIN, HUMAN; PLANT EXTRACT; REPRESSOR PROTEIN; SMALL INTERFERING RNA; STAT3 PROTEIN, HUMAN; WNT1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAGNOLIA; MAGNOLIA GRANDIFLORA; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; MCF-7 CELL LINE; METABOLISM; MOUSE MUTANT; MULTICELLULAR SPHEROID; NUDE MOUSE; OBESITY; PATHOLOGY; PHOSPHORYLATION; PREVENTION AND CONTROL; PROMOTER REGION; RNA INTERFERENCE; TUMOR CELL CULTURE; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BETA CATENIN; BIPHENYL COMPOUNDS; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; DRUGS, CHINESE HERBAL; FEMALE; HISTONE DEACETYLASES; HUMANS; LEPTIN; LIGNANS; MAGNOLIA; MCF-7 CELLS; MICE; MICE, NUDE; MICE, OBESE; MICRORNAS; NEOPLASM INVASIVENESS; OBESITY; PHOSPHORYLATION; PLANT EXTRACTS; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; WNT1 PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937935099     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3844     Document Type: Article

References (50)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA and Ezzati M. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011; 378:31-40.
2. Flegal KM, Carroll MD, Kit BK and Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012; 307:491-497.
3. Calle EE and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004; 4:579-591.
4. Renehan AG, Tyson M, Egger M, Heller RF and Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371:569-578.
5. Reeves GK, Pirie K, Beral V, Green J, Spencer E and Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007; 335:1134.
6. Porter GA, Inglis KM, Wood LA and Veugelers PJ. Effect of obesity on presentation of breast cancer. Ann Surg Oncol. 2006; 13:327-332.
7. Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, Vercelli M, Falcini F and Franceschi S. Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer. 2008; 123:2188-2194.
8. Vona-Davis L, Rose DP, Hazard H, Howard-McNatt M, Adkins F, Partin J and Hobbs G. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev. 2008; 17:3319-3324.
9. Vona-Davis L, Howard-McNatt M and Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 2007; 8:395-408.
10. Vona-Davis L and Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007; 14:189-206.
11. Wu MH, Chou YC, Chou WY, Hsu GC, Chu CH, Yu CP, Yu JC and Sun CA. Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer. 2009; 100:578-582.
12. Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S and Surmacz E. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res. 2006; 12:1447-1453.
13. Knight BB, Oprea-Ilies GM, Nagalingam A, Yang L, Cohen C, Saxena NK and Sharma D. Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer. 2011; 18:413-428.
14. Saxena NK, Vertino PM, Anania FA and Sharma D. leptininduced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to CYCLIN D1 promoter via activation of Stat3. The Journal of biological chemistry. 2007; 282:13316-13325.
15. Yan D, Avtanski D, Saxena NK and Sharma D. Leptininduced epithelial-mesenchymal transition in breast cancer cells requires beta-catenin activation via Akt/GSK3-and MTA1/Wnt1 protein-dependent pathways. The Journal of biological chemistry. 2012; 287:8598-8612.
16. Barone I, Catalano S, Gelsomino L, Marsico S, Giordano C, Panza S, Bonofiglio D, Bossi G, Covington KR, Fuqua SA and Ando S. Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Res. 2012; 72:1416-1427.
17. Ray A and Cleary MP. Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets. 2010; 14:443-451.
18. Saxena NK and Sharma D. Multifaceted leptin network: the molecular connection between obesity and breast cancer. Journal of mammary gland biology and neoplasia. 2013; 18:309-320.
19. Taliaferro-Smith L, Nagalingam A, Knight BB, Oberlick E, Saxena NK and Sharma D. Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis. Neoplasia. 2013; 15:23-38.
20. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 2003; 3(10):768-780.
21. Newman DJ, Cragg GM and Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003; 66:1022-1037.
22. Xu Q, Yi LT, Pan Y, Wang X, Li YC, Li JM, Wang CP and Kong LD. Antidepressant-like effects of the mixture of honokiol and magnolol from the barks of Magnolia officinalis in stressed rodents. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32:715-725.
23. Oh JH, Kang LL, Ban JO, Kim YH, Kim KH, Han SB and Hong JT. Anti-inflammatory effect of 4-O-methylhonokiol, compound isolated from Magnolia officinalis through inhibition of NF-kappaB [corrected]. Chem Biol Interact. 2009; 180:506-514.
24. Choi DY, Lee YJ, Hong JT and Lee HJ. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease. Brain Res Bull. 2012; 87:144-153.
25. Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL and Grandis JR. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010; 16:2571-2579.
26. Fujita M, Itokawa H and Sashida Y. [Studies on the components of Magnolia obovata Thunb. 3. Occurrence of magnolol and honokiol in M. obovata and other allied plants]. Yakugaku Zasshi. 1973; 93:429-434.
27. Nagalingam A, Arbiser JL, Bonner MY, Saxena NK and Sharma D. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast cancer research: BCR. 2012; 14:R35.
28. Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK and Sharma D. Honokiol inhibits epithelialmesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/Ecadherin axis. Molecular oncology. 2014; 8:565-580.
29. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011; 103:1656-1664.
30. Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D and Pusztai L. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat. 2012; 135:619-627.
31. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D and Anania FA. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007; 67:2497-2507.
32. Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O'Regan RM and Sharma D. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer research. 2008; 68:9712-9722.
33. Cadigan KM and Liu YI. Wnt signaling: complexity at the surface. J Cell Sci. 2006; 119:395-402.
34. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, Moon RT, Teo JL, Kim HY, Moon SH, Ha JR and Kahn M. A small molecule inhibitor of beta-catenin/CREBbinding protein transcription [corrected]. Proc Natl Acad Sci U S A. 2004; 101:12682-12687.
35. Henderson WR, Jr., Chi EY, Ye X, Nguyen C, Tien YT, Zhou B, Borok Z, Knight DA and Kahn M. Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A. 2010; 107:14309-14314.
36. Nicoloso MS, Spizzo R, Shimizu M, Rossi S and Calin GA. MicroRNAs--the micro steering wheel of tumour metastases. Nature reviews Cancer. 2009; 9(4):293-302.
37. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL and Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008; 451:147-152.
38. Yang S, Li Y, Gao J, Zhang T, Li S, Luo A, Chen H, Ding F, Wang X and Liu Z. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene. 2013; 32:4294-4303.
39. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A and Mendell JT. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Molecular cell. 2007; 26:745-752.
40. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M and Lund AH. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell death and differentiation. 2010; 17:236-245.
41. Rokavec M, Oner MG, Li H, Jackstadt R, Jiang L, Lodygin D, Kaller M, Horst D, Ziegler PK, Schwitalla S, Slotta-Huspenina J, Bader FG, Greten FR and Hermeking H. IL-6R/STAT3/miR-34a feedback loop promotes EMTmediated colorectal cancer invasion and metastasis. The Journal of clinical investigation. 2014; 124:1853-1867.
42. Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348:1625-1638.
43. Hermeking H. The miR-34 family in cancer and apoptosis. Cell death and differentiation. 2010; 17:193-199.
44. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D and Tang DG. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nature medicine. 2011; 17:211-215.
45. Zhao H, Ma B, Wang Y, Han T, Zheng L, Sun C, Liu T, Zhang Y, Qiu X and Fan Q. miR-34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44. Oncology reports. 2013; 29:1027-1036.
46. Yu G, Li H, Wang J, Gumireddy K, Li A, Yao W, Tang K, Xiao W, Hu J, Xiao H, Lang B, Ye Z, Huang Q and Xu H. miRNA-34a suppresses cell proliferation and metastasis by targeting CD44 in human renal carcinoma cells. The Journal of urology. 2014; 192:1229-1237.
47. Hashimi ST, Fulcher JA, Chang MH, Gov L, Wang S and Lee B. MicroRNA profiling identifies miR-34a and miR-21 and their target genes JAG1 and WNT1 in the coordinate regulation of dendritic cell differentiation. Blood. 2009; 114:404-414.
48. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E, Dubiel W, SoffG and Arbiser JL. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. The Journal of biological chemistry. 2003; 278:35501-35507.
49. Nagalingam A, Tighiouart M, Ryden L, Joseph L, Landberg G, Saxena NK and Sharma D. Med1 plays a critical role in the development of tamoxifen resistance. Carcinogenesis. 2012; 33:918-930.
50. Sharma D and Fondell JD. Ordered recruitment of histone acetyltransferases and the TRAP/Mediator complex to thyroid hormone-responsive promoters in vivo. Proc Natl Acad Sci U S A. 2002; 99:7934-7939.